Cardio-oncology & otherCohort study
Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis
- Retrospective cohort study
- Median follow-up 18 (Q1-Q3: 8-67) weeks
Authors' conclusion
In a contemporary analysis of patients with suspected ICI myocarditis, severe ICI myocarditis was associated with increased 1-year cardiovascular mortality, which was lower than previously reported. Patients with nonsevere ICI myocarditis had outcomes similar to negative cases.
Study context
- Population
- Patients with suspected immune checkpoint inhibitor myocarditis, Massachusetts General Brigham Health System, 2015–2022
- Participants
- 160 patients
- Exposure
- Severe vs nonsevere vs negative immune checkpoint inhibitor (ICI) myocarditis
- Severen = 28
- Nonseveren = 96
- Negativen = 36reference
- Outcome
- CV mortality
- Follow-up
- 1 year
Main finding
As reported in the abstract
1-year CV mortality
Each group vs negativeHazard ratio (95% CI)P value
Severe29% vs 5%; particularly in the early post-myocarditis period
6.52(2.2–19.6)
P < 0.001Nonsevere
0.61(0.14–2.54)
Observational data: associations, not effects.
Further findings
1-year all-cause mortality
- Did not differ between severe, nonsevere and negative cases
- P = 0.74
1-year CV readmissions and long-term LVEF
- Similar among the 3 groups
ICI resumption · 1 year
- Low, even in negative cases
Original publication
Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis. JACC CardioOncol. Published 19 December 2023. doi:10.1016/j.jaccao.2023.09.004
Summarised from the published abstract; every number is checked against it